title: Inhaled budesonide for adults with mild-to-moderate asthma: a randomized placebo-controlled, double-blind clinical trial.
abstract: BACKGROUND
  Budesonide is an inhaled corticosteroid with high topical potency and low systemic activity recommended in the treatment of chronic asthma.
  
  
  OBJECTIVE
  This study was conducted to determine the efficacy and safety of inhaled budesonide via a breath-activated, multi-dose, dry-powder inhaler.
  
  
  METHODS
  Multicenter randomized parallel-group, placebo-controlled, double-blind, clinical trial.
  
  
  METHODS
  Multicenter study in the university units.
  
  
  METHODS
  Adult patients with mild-to-moderate asthma that was not controlled using bronchodilator therapy alone.
  
  
  METHODS
  Comparison of budesonide 400 microg administered twice daily via a breath-activated, multi-dose, dry-powder inhaler with placebo, in 43 adult patients (aged 15 to 78 years) with mild-to-moderate asthma (FEV1 71% of predicted normal) that was not controlled using bronchodilator therapy alone.
  
  
  METHODS
  Efficacy was assessed by pulmonary function tests and asthma symptom control (as perceived by the patients) and the use of rescue medication.
  
  
  RESULTS
  Budesonide 400 microg (bid) was significantly more effective than placebo in improving morning peak expiratory flow (mean difference: 67.9 l/min; P < 0.005) and FEV1 (mean difference: 0.60 l; P < 0.005) over the 8-week treatment period. Onset of action, assessed by morning peak expiratory flow, occurred within the first two weeks of treatment.
  
  
  CONCLUSIONS
  Budesonide via a breath-activated, multi-dose, dry-powder inhaler results in a rapid onset of asthma control, which is maintained over time and is well tolerated in adults with mild-to-moderate asthma.
authors.affiliation: Respirology Division, Hospital São Paulo, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil. analuisa@pneumo.epm.br
authors.forename: A L
authors.initials: AL
authors.lastname: Fernandes
authors.forename: S M
authors.initials: SM
authors.lastname: Faresin
authors.forename: M M
authors.initials: MM
authors.lastname: Amorim
authors.forename: C C
authors.initials: CC
authors.lastname: Fritscher
authors.forename: C A
authors.initials: CA
authors.lastname: Pereira
authors.forename: J R
authors.initials: JR
authors.lastname: Jardim
mesh_terms: D000280:Administration, Inhalation; D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000009:adverse effects / Q000627:therapeutic use; D019819:Budesonide / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005541:Forced Expiratory Volume; D005938:Glucocorticoids; D006801:Humans; D008297:Male; D008875:Middle Aged; D010366:Peak Expiratory Flow Rate; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D001993:Bronchodilator Agents; D005938:Glucocorticoids; D019819:Budesonide